Corcept Therapeutics Incorporated (0I3Q.L)

22,89 +0,09 (+0,39%) Alla chiusura: 06:50PM BST

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 352

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Joseph K. Belanoff M.D.	Co-Founder, President, CEO & Director	2,43M	N/D	1957
Mr. Atabak Mokari	CFO & Treasurer	863,03k	N/D	1977
Mr. Gary Charles Robb	Chief Business Officer & Secretary	1,08M	3,01M	1963
Mr. Joseph Douglas Lyon	Chief Accounting & Technology Officer	N/D	N/D	1978
Ms. Monica Tellado	President of Emerging Markets	N/D	N/D	1973
Mr. Roberto W. Vieira	President of Oncology	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Governance aziendale

L'ISS Governance QualityScore di Corcept Therapeutics Incorporated al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 4; diritti degli azionisti: 6; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.